A Double-blind, Randomized, Placebo-controlled, Multicenter, DoseEscalation Study to Select and Evaluate an Oral Modified Release Formulation of Omecamtiv Mecarbil in Subjects with Heart Failure and Left Ventricular Systolic Dysfunction
- Conditions
- Chronic Heart Failure and Left Ventricular Systolic DysfunctionMedDRA version: 17.0Level: PTClassification code 10063083Term: Chronic left ventricular failureSystem Organ Class: 10007541 - Cardiac disordersTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
- Registration Number
- EUCTR2012-000327-40-HU
- Lead Sponsor
- Amgen Inc.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 544
Dose Escalation Cohorts:
4.1.1 Subject has provided informed consent.
4.1.2 Male or female = 18 years and = 85 years of age at the time of informed consent.
4.1.3 History of chronic HF, defined as requiring treatment for HF for a minimum of 4 weeks prior to screening.
4.1.4 Treated for HF with stable , optimal pharmacological therapy. In general, optimal treatment will include a beta-blocker and an ACE inhibitor and/or an angiotensin receptor blocker at doses shown to be efficacious in HF trials, unless not tolerated. Stable medical therapy is defined as having no new HF drug class introduced or uptitrated = 4 weeks prior to randomization.
4.1.5 LVEF = 40% (echocardiogram, radionuclide ventriculography,
cardiac magnetic resonance imaging, or contrast ventriculography) within 18 months prior to randomization and without an intervening value of > 40%.
4.1.6 NT-proBNP = 200 pg/mL (= 1200 pg/mL if the subject has atrial fibrillation at presentation) at screening; (Note: enrollment of subjects with atrial fibrillation will be limited to up to approximately 20% of planned enrollment in each cohort).
Expansion Phase:
4.1.7 Subject has provided informed consent.
4.1.8 Male or female = 18 years and = 85 years of age at the time of informed consent.
4.1.9 History of chronic HF, defined as requiring treatment for HF for a minimum of 4 weeks prior to screening.
4.1.10 Treated for HF with stable, optimal pharmacological therapy. In general, optimal treatment will include a beta-blocker and an ACE inhibitor and/or an angiotensin receptor blocker at doses shown to be efficacious in HF trials, unless not tolerated. Stable medical therapy is defined as having no new HF drug class introduced or uptitrated = 4 weeks prior to randomization.
4.1.11 NYHA class II or III symptoms.
4.1.12 LVEF = 40% by centrally read screening echocardiogram.
4.1.13 Acceptable echocardiographic image quality of screening
echocardiogram per central echo core laboratory
4.1.14 NT-proBNP = 200 pg/mL (= 23.60 pmol/L) [= 1200 pg/mL (= 141.60 pmol/L) if the subject has atrial fibrillation at presentation] at screening; (Note: enrollment of subjects with atrial fibrillation will be limited to up to approximately 20% of planned cohort enrollment)
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 280
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 290
Dose Escalation Cohorts and Expansion Phase:
4.2.1 Cardiac resynchronization therapy (CRT) or ICD implantation
within 30 days prior to enrollment.
4.2.2 NYHA class IV.
4.2.3 Hospitalization for any reason within 30 days prior to
randomization.
4.2.4 Likely to receive within 3 months after randomization, in the
opinion of the Investigator, planned revascularization, implantation of ICD or CRT, ventricular assist device, continuous or intermittent inotropic therapy, hospice care, or cardiac transplant.
4.2.5 Severe uncorrected valvular heart disease.
4.2.6 Hypertrophic obstructive cardiomyopathy, active myocarditis, or constrictive pericarditis, or clinically significant congenital heart disease.
4.2.7 Acute myocardial infarction, unstable angina or persistent angina at rest within 30 days prior to randomization .
4.2.8 Chronic antiarrhythmic therapy, with the exception of amiodarone.
4.2.9 Routinely scheduled outpatient IV infusions for HF (eg, inotropes, vasodilators [eg, nesiritide], diuretics) or routinely scheduled ultrafiltration.
4.2.10 Systolic BP > 160 mm Hg or < 90 mm Hg, or diastolic BP > 90 mm Hg, or HR > 110 beats per minute (bpm) or HR < 50 bpm at screening.
4.2.11 Estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73m2 at screening.
4.2.12 Currently taking, or has taken within 14 days prior to
randomization, a potent CYP3A4 inhibitor.
4.2.13 Currently taking, or has taken within 28 days prior to
randomization, a potent CYP3A4 inducer.
4.2.14 Severe, concomitant noncardiovascular disease that is expected to reduce life expectancy to less than 1 year.
4.2.15 Recipient of any major organ transplant (eg, lung, liver, heart, bone marrow, renal) or receiving renal replacement therapy by dialysis.
4.2.16 Malignancy within 5 years prior to randomization with the
following exceptions: localized basal or squamous cell carcinoma of the skin or cervical intraepithelial neoplasia.
4.2.17 Known untreated hypothyroidism or hyperthyroidism, adrenal
insufficiency, active vasculitis due to collagen vascular disease.
4.2.18 Hepatic impairment
4.2.19 Any acute or serious co-morbid condition (eg, major infection or hematologic, renal, metabolic, gastrointestinal or endocrine dysfunction) that, in the judgment of the investigator, could lead to premature termination of study participation or interfere with the measurement of, or the interpretation of, the efficacy and safety assessments in the study
4.2.20 Previously received omecamtiv mecarbil.
4.2.21 Currently receiving treatment in another investigational device or drug study, or less than 30 days since ending treatment on another investigational device or drug study.
4.2.22 Recent (within 3 months) history of alcohol or illicit drug abuse based on self-report.
4.2.23 Known sensitivity to any of the products to be administered during dosing.
4.2.24 Female subject of childbearing potential who is not willing to inform her partner of her participation in this clinical study and to use two acceptable methods of effective birth control or abstinence or surgical contraceptive methods (vasectomy or bilateral tubal ligation) during treatment with IP (omecamtiv mecarbil or placebo) and for an additional 5 days after the last dose of IP. Male subject with a female partner of childbearing potential and not willing to inform his partner of his participation in this clinical study
- A female is considered of chilbearing potential unless she has had a hysterectomy,
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method